Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphoma

Nivolumab in Advanced Hodgkin’s Lymphoma | NEJMПодробнее

SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphomaПодробнее

Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patientsПодробнее

SWOG S1826 Study Design Discussion in Hodgkin's Lymphoma Patients #oncology #cancer #2023Подробнее

ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 studyПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

Nivolumab-AVD improved PFS versus brentuximab vedotin-AVD in patients with advanced stage HLПодробнее

Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma PatientsПодробнее

Updates on the use of nivolumab in Hodgkin lymphoma & how this agent may impact treatmentПодробнее

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin LymphomaПодробнее

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin LymphomaПодробнее

NIVAHL: nivolumab and AVD in early-stage unfavorable HLПодробнее

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin LymphomaПодробнее

Novel agents for the treatment of Hodgkin lymphoma: brentuximab vedotin and nivolumabПодробнее

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphomaПодробнее

Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphomaПодробнее